Fresenius Kabi – Oncology & Critical Care Medicines

Fresenius Kabi

Country: Germany

Fresenius Kabi is a German healthcare company within the Fresenius SE & Co. KGaA group, headquartered in Bad Homburg, Hesse. The parent company's shares are listed on the Frankfurt Stock Exchange. Fresenius Kabi took its present form in 1999, when Fresenius merged its pharmaceutical business with the international clinical nutrition business it had bought from Pharmacia & Upjohn.

The company specialises in medicines and technologies for infusion, transfusion and clinical nutrition. Its portfolio includes generic intravenous drugs (including for oncology, anaesthesia and intensive care), infusion solutions, parenteral and enteral nutrition, and medical devices such as infusion pumps, blood transfusion systems and disposables.

Fresenius Kabi also develops biosimilars for autoimmune diseases and cancer: in 2017 it bought the biosimilars business of Merck KGaA, and in 2022 it acquired a majority stake in Spain's mAbxience.

In 2008 Fresenius Kabi bought a controlling stake in India's Dabur Pharma, which became the basis of its oncology business in India, and acquired APP Pharmaceuticals in the US.

Unifarm carries Indian-made Fresenius Kabi medicines: Thalix 50 and Thalix-100 (thalidomide), used in multiple myeloma.

Official manufacturer website
Fresenius Kabi

List of medicines by manufacturer Fresenius Kabi

-17%
Thalix 50
View
Fresenius Kabi
50 mg 30 capsules
1120₴ 1350₴
-13%
Thalix-100
View
Fresenius Kabi
100 mg 30 capsules
1565₴ 1788₴
✅ All products loaded (2)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00